Health

A study highlighted by Medical Xpress says the brain’s default mode network may be organized into distinct sender and receiver zones, adding a new layer to how scientists think about internally focused cognition.

A new Medical Xpress essay challenges the idea of the human body as a perfectly engineered machine, arguing instead that anatomy reflects evolutionary compromise.

An experimental gene-silencing drug reduced a Parkinson’s-linked protein by as much as 60% in an early human study, offering a measurable biological signal while leaving larger questions about clinical benefit for later,

A new systematic review and meta-analysis reports that occupational exposure to talc not contaminated with asbestos was not associated with increased risk across the respiratory cancers examined, adding an important dist

A new STAT reader-letters package puts a narrow but important question back on the table: whether gaps in nutrition education are a core weakness in prevention-focused care, or only one piece of a bigger structural issue

STAT+ has published its latest roundup of hires, departures, promotions, and transfers across pharma and biotech, underscoring how personnel changes remain a closely watched signal inside the industry.

Replimune’s skin cancer therapy has reportedly been rejected by the FDA again, extending a high-profile regulatory setback that had already become a flashpoint in agency debates.

A newly published charter for the CDC’s vaccine advisory panel adds an explicit focus on vaccine safety after a judge suspended most Trump administration appointments to the committee.

An Endpoints News report says five beta thalassemia patients treated with a Chinese gene-editing therapy no longer need regular transfusions, hinting at rising global competition in genetic medicine.

A new China-U.S. biotech raised $54 million for preclinical RNA therapies, while Wegovy distribution rules changed in Europe and Gilead exercised a $45 million Kymera option.

After spending years concentrating on existing portfolios, biotech venture capital firms are beginning to fund new opportunities again, signaling a cautious return to risk in the sector.

Novo Nordisk is navigating two departures at once, including the retirement of GLP-1 pioneer Lotte Bjerre Knudsen and the loss of an obesity leader to Boehringer Ingelheim.

Oricell Therapeutics has added another $40 million to what it describes as a pre-IPO financing, taking total funds raised past $110 million. The company is focused on CAR-T therapies for solid tumors.

Roche is expanding work with longtime partner C4 Therapeutics in a deal worth $20 million upfront, underscoring rising interest in degrader-antibody conjugates as a new twist on an already hot cancer-drug category.

AbbVie has sued the federal government over how it interprets the word “patient” in the 340B drug discount program, opening a new front in one of the most consequential pricing disputes in U.S. healthcare.

A new report says a novel gene-based therapy helped nerves heal better after severe peripheral injury, offering a potential advance for patients who often face lasting weakness, numbness, or loss of function.

Children born before 24 weeks of gestation are associated with high societal costs across childhood, with the heaviest burden in the first year of life and support needs continuing for years afterward.

A large trial in India found two new tuberculosis vaccines were safe in adults and children, but neither delivered broad protection against all forms of TB.

A federal judge declined Louisiana officials’ request to halt nationwide mail delivery of mifepristone while litigation continues, preserving the current status quo for now.

Researchers at Karolinska Institutet report an association between gut bacteria composition and the level of latent HIV in people receiving antiretroviral therapy, pointing to a possible new line of investigation in cure